// App-Quantinova.ai

OR26-3 : Biochemical and Physical Function Outcomes in Adolescents and Adults with Hypophosphatasia Treated with Asfotase Alfa for up to 4 Years: Interim Results from a Phase II Study

Researchers

Presenter

  • Katherine L Madson

Principal Investigators

  • Michael P Whyte

  • Marisa Gayron

  • Kenji Fujita

  • Cheryl Rockman-Greenberg

Medical Centers

  • Shriners Hosp for Children, Saint Louis, MO

  • Duke University Medical Center, Durham, NC

Locations

  • United States

  • Canada

Companies

  • Alexion Pharmaceutic

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Hypophosphatasia

Biomarkers

  • Alkaline phosphatase

  • Alkaline Phosphatase, Biomineralization Associated

  • Myelin proteolipid protein

Drug/Treatment

  • Alkaline phosphatase

  • Strensiq

Outcome

  • N/A

Study Design

  • open label

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved